Home/Pipeline/Evrysdi

Evrysdi

Spinal muscular atrophy

CommercialActive

Key Facts

Indication

Spinal muscular atrophy

Phase

Commercial

Status

Active

Company

Royalty Pharma

About Royalty Pharma

Founded in 1996, Royalty Pharma pioneered the royalty pharma asset class by providing non-dilutive capital to pharmaceutical innovators. The company has deployed over $19 billion to acquire royalty interests in leading medicines across multiple therapeutic areas. As a publicly-traded company on NASDAQ, Royalty Pharma generates revenue from royalty payments on successful drugs while helping fund the next generation of medical breakthroughs.

View full company profile

Therapeutic Areas

Oncology Immunology Neurology Respiratory Rare Diseases Infectious Disease

Other Spinal muscular atrophy Drugs

Drug	Company	Phase	Status
GYM329	Chugai Pharmaceutical	Phase 2	Active
Spinraza	Royalty Pharma	Commercial	Active
Spinal Muscular Atrophy Program	Biogen	Commercial	Active
ASO Candidates for SMA	Biogen	Pre-clinical	Active
SPINRAZA (nusinersen)	Ionis Pharmaceuticals	Approved	Partnered/marketed